clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2023-101-11-525-530clinmed-649Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESПервичный гиперальдостеронизм: выбор в пользу органосохраняющих операцийPrimary hyperaldosteronism: the choice in favor of conservative surgeryhttps://orcid.org/0000-0001-9911-3117АннаевМ. С.AnnayevM. S.

Аннаев Мейлис Сердарович  — аспирант школы медицины ДВФУ

690922, Владивосток

Annayev Meilis S.

690922, Vladivostok

dr.meylis.card@gmail.comhttps://orcid.org/0000-0003-0472-9504СтегнийК. В.StegniyK. V.

Стегний Кирилл Владимирович — д-р мед. наук, профессор, член-корр. РАН, директор школы медицины ДВФУ

690922, Владивосток

Stegniy Kirill V.

690922, Vladivostok

https://orcid.org/0000-0002-9250-557XГельцерБ. И.GeltserB. I.

Гельцер Борис Израйльевич — д-р мед. наук, профессор, член-корр. РАН, заместитель директора по научной работе школы медицины ДВФУ

690922, Владивосток

Geltser Boris I.

690922, Vladivostok

https://orcid.org/0000-0002-6261-7511ГончарукР. А.GoncharukR. A.

Гончарук Роман Анатольевич — канд. мед. наук, врач-хирург, онколог медицинского центра ДВФУ 

690922, Владивосток

Goncharuk Roman A.

690922, Vladivostok

https://orcid.org/0000-0003-2387-6518МорозоваА. М.MorozovaA. M.

Морозова Алла Моисеевна  — канд. мед. наук, доцент департамента дополнительного образования и ординатуры школы медицины ДВФУ 

690922, Владивосток

Morozova Alla M.

690922, Vladivostok

https://orcid.org/0000-0002-1074-1000МаслянцевЕ. В.MaslyantsevE. V.

Маслянцев Евгений Владимирович  — ассистент департамента клинической медицины школы медицины, врач-хирург центра хирургии медицинского центра ДВФУ

690922, Владивосток

Maslyantsev Evgeny V.

690922, Vladivostok

ФГАОУ ВО «Дальневосточный федеральный университет»РоссияFar Eastern Federal UniversityRussian Federation20231212202310111525530Copyright © Аннаев М.С., Стегний К.В., Гельцер Б.И., Гончарук Р.А., Морозова А.М., Маслянцев Е.В., 20232023Аннаев М.С., Стегний К.В., Гельцер Б.И., Гончарук Р.А., Морозова А.М., Маслянцев Е.В.Annayev M.S., Stegniy K.V., Geltser B.I., Goncharuk R.A., Morozova A.M., Maslyantsev E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/649

Первичный гиперальдостеронизм (ПГА) является наиболее распространенной причиной вторичной артериальной гипертензии среди эндокринных заболеваний. Учитывая, что пациенты с данной патологией подвержены более высокому риску развития фатальных и нефатальных сердечно-сосудистых событий, большое значение имеют ранняя диагностика заболевания и его своевременное лечение. На сегодняшний день в центре внимания находятся две основные формы ПГА: альдостеронпродуцирующая аденома и двусторонняя гиперплазия надпочечников, лечение которых обеспечивается выполнением лапароскопической адреналэктомии или фармакотерапией антагонистами минерало-кортикоидных рецепторов. Несмотря на то что у большинства пациентов после хирургического вмешательства наблюдается восстановление функционально-метаболического статуса, у части из них фиксируется развитие послеоперационной надпочечниковой недостаточности. Это в свою очередь приводит к необходимости длительной гормонозаместительной терапии. В обзоре рассмотрены варианты применения органосохраняющих операций (частичная адреналэктомия и селективная эмболизация надпочечниковой артерии)

Primary hyperaldosteronism (PHA) is the most common cause of secondary arterial hypertension among endocrine disorders.  Given that patients with this pathology are at a higher risk of developing fatal and non-fatal cardiovascular events, early  diagnosis and timely treatment are of great importance. Currently, the two main forms of PHA are aldosterone-producing  adenoma and bilateral adrenal hyperplasia, which are treated with laparoscopic adrenalectomy or pharmacotherapy with  mineralocorticoid receptor antagonists. Although most patients experience restoration of their functional and metabolic  status after surgical intervention, some may develop postoperative adrenal insuffi ciency, which requires long-term hormone  replacement therapy. This review examines the options for organ-preserving surgeries, such as partial adrenalectomy and  selective embolization of the adrenal artery.

инциденталомы надпочечниковпервичный гиперальдостеронизмнадпочечниковая недостаточностьлапароскопическая адреналэктомиячастичная адреналэктомияселективная эмболизация надпочечниковых артерийadrenal incidentalomasprimary hyperaldosteronismadrenal insuffi ciencylaparoscopic adrenalectomypartial adrenalectomyselective embolization of the adrenal arteriesReferencesБельцевич Д.Г., Трошина Е.А., Мельниченко Г.А., Платонова Н.М., Ладыгина Д.О., Шевэ А. Проект клинических рекомендаций «инциденталома надпочечника». Эндокринная хирургия. 2020;15(1):4–26. DOI: org/10.14341/serg12712Beltsevich D.G., Troshina E.A., Melnichenko G.A., Platonova N.M., Ladygina D.O., Sheve A. Draft of the clinical practice guidelines “adrenal incidentaloma”. J. Endocrine Surgery. 2021;15(1):4–26. (In Russian)]. DOI: org/10.14341/serg12712Chatzellis E., Kaltsas G. Adrenal Incidentalomas. 2019 Nov 7. In: Feingold K.R., Anawalt B., Blackman M.R., Boyce A., Chrousos G., Corpas E., de Herder W.W., Dhatariya K., Hofl and J., Dungan K., Hofl and J., Kalra S., Kaltsas G., Kapoor N., Koch C., Kopp P., Korbonits M., Kovacs C.S., Kuohung W., Laferrère B., Levy M., McGee E.A., McLachlan R., New M., Purnell J., Sahay R., Singer F., Sperling M.A., Stratakis C.A., Trence D.L., Wilson D.P., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000.Chatzellis E., Kaltsas G. Adrenal Incidentalomas. 2019 Nov 7. In: Feingold K.R., Anawalt B., Blackman M.R., Boyce A., Chrousos G., Corpas E., de Herder W.W., Dhatariya K., Hofl and J., Dungan K., Hofl and J., Kalra S., Kaltsas G., Kapoor N., Koch C., Kopp P., Korbonits M., Kovacs C.S., Kuohung W., Laferrère B., Levy M., McGee E.A., McLachlan R., New M., Purnell J., Sahay R., Singer F., Sperling M.A., Stratakis C.A., Trence D.L., Wilson D.P., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000.Мурадян А.Г., Костин А.А., Воробьев Н.В., Толкачев А.О. Метастатические опухоли надпочечника. Эпидемиология, этиология, диагностика. Онкология. Журнал им. П.А. Герцена. 2020;9(3):53–60. DOI: 10.17116/onkolog2020903153Muradyan A.G., Kostin A.A., Vorobiov N.V., Tolkachev A.O. Metastatic adrenal tumors. Epidemiology, etiology, diagnosis. P.A. Herzen Journal of Oncology = Onkologiya. Zhurnal im. P.A. Gertsena. 2020;9(3):53–60. (In Russian). DOI: 10.17116/onkolog2020903153Уильям Я., Ладыгина Д.О., Балутина О.В., Бельцевич Д.Г. Первичный гиперальдостеронизм: подход клиники Мэйо. Терапевтический архив. 2020;92(10):83–87. DOI: 10.26442/00403660.2020.10.000754Young W., Ladygina D.O., Balutina O.V., Beltsevich D.G. Primary aldosteronism: The Mayo clinic approach. Therapeutic Archive. 2020;92(10):83–87. (In Russian). DOI: 10.26442/00403660.2020.10.000754Мельниченко Г.А., Платонова Н.М., Бельцевич Д.Г., Юкина М.Ю., Молашенко Н.В., Трошина Е.А. Первичный гиперальдостеронизм: диагностика и лечение. Новый взгляд на проблему. По материалам Проекта клинических рекомендаций Российской ассоциации эндокринологов по диагностике и лечению первичного гиперальдостеронизма. Consilium Medicum. 2017;19(4):75–85.Melnichenko G.A., Platonova N.M., Beltsevich D.G., Yukina I., Molashenko N.V., Troshina E.A. Primary hyperaldosteronism: diagnosis and treatment. A new look at the problem. According to the materials of the Russian Association of Endocrinologists clinical guidelines for primary hyperaldosteronism diagnosis and treatment. Consilium Medicum. 2017;19(4):75–85. (In Russian).Huang W.C., Lin Y.H., Wu V.C., Chen C.H., Siddique S., Chia Y.C., Tay J.C., Sogunuru G., Cheng H.M., Kario K. Who should be screened for primary aldosteronism? A comprehensive review of current evidence. J. Clin. Hypertens. (Greenwich). 2022;24(9):1194– 1203. DOI: 10.1111/jch.14558Huang W.C., Lin Y.H., Wu V.C., Chen C.H., Siddique S., Chia Y.C., Tay J.C., Sogunuru G., Cheng H.M., Kario K. Who should be screened for primary aldosteronism? A comprehensive review of current evidence. J. Clin. Hypertens. (Greenwich). 2022;24(9):1194– 1203. DOI: 10.1111/jch.14558Monticone S., D'Ascenzo F., Moretti C., Williams T.A., Veglio F., Gaita F., Mulatero P. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41–50. DOI: 10.1016/S2213-8587(17)30319-4Monticone S., D'Ascenzo F., Moretti C., Williams T.A., Veglio F., Gaita F., Mulatero P. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41–50. DOI: 10.1016/S2213-8587(17)30319-4Хамнуева Л.Ю., Андреева Л.С., Токарева Н.П., Новожилов А.В., Ефимов А.А., Рожанская Е.В. Диагностика и лечение альдостерон-продуцирующей аденомы у молодого пациента: клиническое наблюдение. Альманах клинической медицины. 2021;49(5):335–341. DOI: 10.18786/2072-0505-2021-49-039Khamnueva L.Yu., Andreeva L.S., Tokareva N.P., Novozhilov A.V., Efi mov A.A., Rozhanskaya E.V. Diagnosis and treatment of aldosterone-producing adenoma in a young patient: a clinical case. Clinical Medicine Almanac. 2021;49(5):335– 341 (In Russian). DOI: 10.18786/2072-0505-2021-49-039Hiramatsu K., Yamada T., Yukimura Y., Komiya I., Ichikawa K., Ishihara M., Nagata H., Izumiyama T. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch. Intern. Med. 1981;141(12):1589–93. DOI:10.1001/archinte.1981.00340130033011Hiramatsu K., Yamada T., Yukimura Y., Komiya I., Ichikawa K., Ishihara M., Nagata H., Izumiyama T. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch. Intern. Med. 1981;141(12):1589–93. DOI:10.1001/archinte.1981.00340130033011Gan W., Lin W., Ouyang J., Li Y., Chen D., Yao Z., Feng P. High effi ciency of the aldosterone-to-renin ratio in precisely detecting primary aldosteronism. J. Hum. Hypertens. 2019;33(1):57–61. DOI: 10.1038/s41371-018-0112-8Gan W., Lin W., Ouyang J., Li Y., Chen D., Yao Z., Feng P. High effi ciency of the aldosterone-to-renin ratio in precisely detecting primary aldosteronism. J. Hum. Hypertens. 2019;33(1):57–61. DOI: 10.1038/s41371-018-0112-8Schilbach K., Junnila R.K., Bidlingmaier M. Aldosterone to Renin Ratio as Screening Tool in Primary Aldosteronism. Exp. Clin. Endocrinol. Diabetes. 2019;127(02–03):84–92. DOI: 10.1055/a-0672-0836Schilbach K., Junnila R.K., Bidlingmaier M. Aldosterone to Renin Ratio as Screening Tool in Primary Aldosteronism. Exp. Clin. Endocrinol. Diabetes. 2019;127(02–03):84–92. DOI: 10.1055/a-0672-0836Ariens J., Horvath A.R., Yang J., Choy K.W. Performance of the aldosterone-to-renin ratio as a screening test for primary aldosteronism in primary care. Endocrine. 2022;77(1):11–20. DOI: 10.1007/s12020-022-03084-xAriens J., Horvath A.R., Yang J., Choy K.W. Performance of the aldosterone-to-renin ratio as a screening test for primary aldosteronism in primary care. Endocrine. 2022;77(1):11–20. DOI: 10.1007/s12020-022-03084-xHung A., Ahmed S., Gupta A., Davis A., Kline G.A., Leung A.A., Ruzicka M., Hiremath S., Hundemer G.L. Performance of the Aldosterone to Renin Ratio as a Screening Test for Primary Aldosteronism. J. Clin. Endocrinol. Metab. 2021;106(8):2423–2435. DOI: 10.1210/clinem/dgab348Hung A., Ahmed S., Gupta A., Davis A., Kline G.A., Leung A.A., Ruzicka M., Hiremath S., Hundemer G.L. Performance of the Aldosterone to Renin Ratio as a Screening Test for Primary Aldosteronism. J. Clin. Endocrinol. Metab. 2021;106(8):2423–2435. DOI: 10.1210/clinem/dgab348Чихладзе Н.М. Первичный гиперальдостеронизм: показания для скрининга. Терапевтический архив. 2022;94(1):107–113. DOI: 10.26442/00403660.2022.01.201324Chikhladze N.M. Primary hyperaldosteronism: indications for screening. Therapeutic Archive. 2022;94(1):107–113. (In Russian). DOI: 10.2 6442/00403660.2022.01.201324Stowasser M., Ahmed A.H., Pimenta E., Taylor P.J., Gordon R.D. Factors aff ecting the aldosterone/renin ratio. Horm. Metab. Res. 2012;44(3):170–6. DOI: 10.1055/s-0031-1295460Stowasser M., Ahmed A.H., Pimenta E., Taylor P.J., Gordon R.D. Factors aff ecting the aldosterone/renin ratio. Horm. Metab. Res. 2012;44(3):170–6. DOI: 10.1055/s-0031-1295460Alnazer R.M., Veldhuizen G.P., Kroon A.A., de Leeuw P.W. The effect of medication on the aldosterone-to-renin ratio. A critical review of the literature. J. Clin. Hypertens. (Greenwich). 2021;23(2):208– 214. DOI: 10.1111/jch.14173Alnazer R.M., Veldhuizen G.P., Kroon A.A., de Leeuw P.W. The effect of medication on the aldosterone-to-renin ratio. A critical review of the literature. J. Clin. Hypertens. (Greenwich). 2021;23(2):208– 214. DOI: 10.1111/jch.14173Veldhuizen G.P., Alnazer R.M., Kroon A.A., de Leeuw P.W. Confounders of the aldosterone-to-renin ratio when used as a screening test in hypertensive patients: A critical analysis of the literature. J. Clin. Hypertens. (Greenwich). 2021;23(2):201–207. DOI: 10.1111/jch.14117Veldhuizen G.P., Alnazer R.M., Kroon A.A., de Leeuw P.W. Confounders of the aldosterone-to-renin ratio when used as a screening test in hypertensive patients: A critical analysis of the literature. J. Clin. Hypertens. (Greenwich). 2021;23(2):201–207. DOI: 10.1111/jch.14117Funder J.W., Carey R.M., Mantero F., Murad M.H., Reincke M., Shibata H., Stowasser M., Young W.F. Jr. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2016;101(5):1889–916. DOI: 10.1210/jc.2015-4061Funder J.W., Carey R.M., Mantero F., Murad M.H., Reincke M., Shibata H., Stowasser M., Young W.F. Jr. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2016;101(5):1889–916. DOI: 10.1210/jc.2015-4061Naruse M., Katabami T., Shibata H., Sone M., Takahashi K., Tanabe A., Izawa S., Ichijo T., Otsuki M., Omura M., Ogawa Y., Oki Y., Kurihara I., Kobayashi H., Sakamoto R., Satoh F., Takeda Y., Tanaka T., Tamura K., Tsuiki M., Hashimoto S., Hasegawa T., Yoshimoto T., Yoneda T., Yamamoto K., Rakugi H., Wada N., Saiki A., Ohno Y., Haze T. Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. Endocr. J. 2022;69(4):327-359. DOI: 10.1507/endocrj.EJ21-0508Naruse M., Katabami T., Shibata H., Sone M., Takahashi K., Tanabe A., Izawa S., Ichijo T., Otsuki M., Omura M., Ogawa Y., Oki Y., Kurihara I., Kobayashi H., Sakamoto R., Satoh F., Takeda Y., Tanaka T., Tamura K., Tsuiki M., Hashimoto S., Hasegawa T., Yoshimoto T., Yoneda T., Yamamoto K., Rakugi H., Wada N., Saiki A., Ohno Y., Haze T. Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. Endocr. J. 2022;69(4):327-359. DOI: 10.1507/endocrj.EJ21-0508Russmann M.L. E., Delfi no L., Fierro F., Santoro S., Peréz M., Caruso G., Glikman P., Gauna A., Lupi S. Primary aldosteronism: Aldosterone/renin ratio cut-off points. Endocrinol. Diabetes Nutr. (Engl. Ed.). 2019;66(6):361–367. English, Spanish. DOI: 10.1016/j.endinu.2018.11.008Russmann M.L. E., Delfi no L., Fierro F., Santoro S., Peréz M., Caruso G., Glikman P., Gauna A., Lupi S. Primary aldosteronism: Aldosterone/renin ratio cut-off points. Endocrinol. Diabetes Nutr. (Engl. Ed.). 2019;66(6):361–367. English, Spanish. DOI: 10.1016/j.endinu.2018.11.008Yoon M., Hong N., Ha J., Lee CJ., Ku C.R., Rhee Y., Park S. Prevalence and clinical characteristics of primary aldosteronism in a tertiary-care center in Korea. Hypertens. Res. 2022;45(9):1418–1429. DOI: 10.1038/s41440-022-00948-7Yoon M., Hong N., Ha J., Lee CJ., Ku C.R., Rhee Y., Park S. Prevalence and clinical characteristics of primary aldosteronism in a tertiary-care center in Korea. Hypertens. Res. 2022;45(9):1418–1429. DOI: 10.1038/s41440-022-00948-7Kempers M.J., Lenders J.W., van Outheusden L., van der Wilt G.J., Schultze Kool L.J., Hermus A.R., Deinum J. Systematic review: diagnostic procedures to diff erentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. J. Ann. Intern. Med. 2009;151(5):329–37. DOI: 10.7326/0003-4819-151-5-200909010-00007Kempers M.J., Lenders J.W., van Outheusden L., van der Wilt G.J., Schultze Kool L.J., Hermus A.R., Deinum J. Systematic review: diagnostic procedures to diff erentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. J. Ann. Intern. Med. 2009;151(5):329–37. DOI: 10.7326/0003-4819-151-5-200909010-00007Ladurner R., Sommerey S., Buechner S., Dietz A., Degenhart C., Hallfeldt K., Gallwas J. Accuracy of adrenal imaging and adrenal venous sampling in diagnosing unilateral primary aldosteronism. Eur. J. Clin. Invest. 2017;47(5):372–377. DOI: 10.1111/eci.12746Ladurner R., Sommerey S., Buechner S., Dietz A., Degenhart C., Hallfeldt K., Gallwas J. Accuracy of adrenal imaging and adrenal venous sampling in diagnosing unilateral primary aldosteronism. Eur. J. Clin. Invest. 2017;47(5):372–377. DOI: 10.1111/eci.12746Betz M.J., Zech C.J. Adrenal venous sampling in the diagnostic workup of primary aldosteronism. Br. J. Radiol. 2022;95(1129):20210311. DOI: 10.1259/bjr.20210311Betz M.J., Zech C.J. Adrenal venous sampling in the diagnostic workup of primary aldosteronism. Br. J. Radiol. 2022;95(1129):20210311. DOI: 10.1259/bjr.20210311Addison T. on the constitutional and local eff ects of disease of the supra-renal capsules. London, UK: Samuel Highley; 1855.Addison T. on the constitutional and local eff ects of disease of the supra-renal capsules. London, UK: Samuel Highley; 1855.Barthel A., Benker G., Berens K., Diederich S., Manfras B., Gruber M., Kanczkowski W., Kline G., Kamvissi-Lorenz V., Hahner S., Beuschlein F., Brennand A., Boehm B.O., Torpy D.J., Bornstein S.R. An Update on Addi’on's Disease. J. Exp. Clin. Endocrinol. Diabetes. 2019;127(2-03):165–175. DOI: 10.1055/a-0804-2715Barthel A., Benker G., Berens K., Diederich S., Manfras B., Gruber M., Kanczkowski W., Kline G., Kamvissi-Lorenz V., Hahner S., Beuschlein F., Brennand A., Boehm B.O., Torpy D.J., Bornstein S.R. An Update on Addi’on's Disease. J. Exp. Clin. Endocrinol. Diabetes. 2019;127(2-03):165–175. DOI: 10.1055/a-0804-2715Di Dalmazi G., Berr C.M., Fassnacht M., Beuschlein F., Reincke M. Adrenal function after adrenalectomy for subclinical hypercortisolism and Cush’ng's syndrome: a systematic review of the literature. J. Clin. Endocrinol. Metab. 2014;99(8):2637–45. DOI: 10.1210/jc.2014-1401Di Dalmazi G., Berr C.M., Fassnacht M., Beuschlein F., Reincke M. Adrenal function after adrenalectomy for subclinical hypercortisolism and Cush’ng's syndrome: a systematic review of the literature. J. Clin. Endocrinol. Metab. 2014;99(8):2637–45. DOI: 10.1210/jc.2014-1401Kulshreshtha B., Arora A., Aggarwal A., Bhardwaj M. Prolonged adrenal insuffi ciency after unilateral adrenalectomy for Cush’ng's Syndrome. Indian J. Endocrinol Metab. 2015;19(3):430–2. DOI: 10.4103/2230-8210.152794Kulshreshtha B., Arora A., Aggarwal A., Bhardwaj M. Prolonged adrenal insuffi ciency after unilateral adrenalectomy for Cush’ng's Syndrome. Indian J. Endocrinol Metab. 2015;19(3):430–2. DOI: 10.4103/2230-8210.152794Fischer E., Hanslik G., Pallauf A., Degenhart C., Linsenmaier U., Beuschlein F., Bidlingmaier M., Mussack T., Ladurner R., Hallfeldt K., Quinkler M., Reincke M. Prolonged zona glomerulosa insuffi ciency causing hyperkalemia in primary aldosteronism after adrenalectomy. J. Clin. Endocrinol. Metab. 2012;97(11):3965–73. DOI: 10.1210/jc.2012-2234Fischer E., Hanslik G., Pallauf A., Degenhart C., Linsenmaier U., Beuschlein F., Bidlingmaier M., Mussack T., Ladurner R., Hallfeldt K., Quinkler M., Reincke M. Prolonged zona glomerulosa insuffi ciency causing hyperkalemia in primary aldosteronism after adrenalectomy. J. Clin. Endocrinol. Metab. 2012;97(11):3965–73. DOI: 10.1210/jc.2012-2234Park K.S., Kim J.H., Ku E.J., Hong A.R., Moon M.K., Choi S.H., Shin C.S., Kim S.W., Kim S.Y. Clinical risk factors of postoperative hyperkalemia after adrenalectomy in patients with aldosterone-producing adenoma. Eur. J. Endocrinol. 2015;172(6):725–31. DOI: 10.1530/EJE-15-0074Park K.S., Kim J.H., Ku E.J., Hong A.R., Moon M.K., Choi S.H., Shin C.S., Kim S.W., Kim S.Y. Clinical risk factors of postoperative hyperkalemia after adrenalectomy in patients with aldosterone-producing adenoma. Eur. J. Endocrinol. 2015;172(6):725–31. DOI: 10.1530/EJE-15-0074Heinrich D.A., Adolf C., Holler F., Lechner B., Schneider H., Riester A., Nirschl N., Sturm L., Wang X., Ladurner R., Seidensticker M., Bidlingmaier M., Beuschlein F., Reincke M. Adrenal insuffi ciency after unilateral adrenalectomy in primary aldosteronism: long-term outcome and clinical impact. J. Clin. Endocrinol. Metab. 2019;104(11):5658–5664. DOI: 10.1210/jc.2019-00996Heinrich D.A., Adolf C., Holler F., Lechner B., Schneider H., Riester A., Nirschl N., Sturm L., Wang X., Ladurner R., Seidensticker M., Bidlingmaier M., Beuschlein F., Reincke M. Adrenal insuffi ciency after unilateral adrenalectomy in primary aldosteronism: long-term outcome and clinical impact. J. Clin. Endocrinol. Metab. 2019;104(11):5658–5664. DOI: 10.1210/jc.2019-00996Alesina P.F., Knyazeva P., Hinrichs J., Walz M.K. Tailored Approach in Adrenal Surgery: Retroperitoneoscopic Partial Adrenalectomy. Front Endocrinol. (Lausanne). 2022;13:855326. DOI: 10.3389/fendo.2022.855326. PMID: 35418944; PMCID: PMC8995530Alesina P.F., Knyazeva P., Hinrichs J., Walz M.K. Tailored Approach in Adrenal Surgery: Retroperitoneoscopic Partial Adrenalectomy. Front Endocrinol. (Lausanne). 2022;13:855326. DOI: 10.3389/fendo.2022.855326. PMID: 35418944; PMCID: PMC8995530Brauckhoff M., Stock K., Stock S., Lorenz K., Sekulla C., Brauckhoff K., Thanh P.N., Gimm O., Spielmann R.P., Dralle H. Limitations of intraoperative adrenal remnant volume measurement in patients undergoing subtotal adrenalectomy. World J. Surg. 2008;32(5):86372. DOI: 10.1007/s00268-007-9402-yBrauckhoff M., Stock K., Stock S., Lorenz K., Sekulla C., Brauckhoff K., Thanh P.N., Gimm O., Spielmann R.P., Dralle H. Limitations of intraoperative adrenal remnant volume measurement in patients undergoing subtotal adrenalectomy. World J. Surg. 2008;32(5):86372. DOI: 10.1007/s00268-007-9402-yWalz M.K. Nebennierenresektion zum Erhalt der adrenokortikalen Funktion. Indikationen und Ergebnisse [Adrenalectomy for preservation of adrenocortical function. Indication and results]. Chirurg. 2009;80(2):99–104. German. DOI: 10.1007/s00104-008-1612-9Walz M.K. Nebennierenresektion zum Erhalt der adrenokortikalen Funktion. Indikationen und Ergebnisse [Adrenalectomy for preservation of adrenocortical function. Indication and results]. Chirurg. 2009;80(2):99–104. German. DOI: 10.1007/s00104-008-1612-9Li K.P., Duan X., Yang X.S., Huang J., Wu T. Partial versus total adrenalectomy for the treatment of unilateral aldosterone-producing adenoma: a systematic review and meta-analysis. Updates Surg. 2021;73(6):2301–2313. DOI: 10.1007/s13304-021-01116-1Li K.P., Duan X., Yang X.S., Huang J., Wu T. Partial versus total adrenalectomy for the treatment of unilateral aldosterone-producing adenoma: a systematic review and meta-analysis. Updates Surg. 2021;73(6):2301–2313. DOI: 10.1007/s13304-021-01116-1Miron A., Giulea C., Nădrăgea M., Enciu O Laparoscopic Partial Adrenalectomy. Chirurgia (Bucur). 2017;112(1):77–81. DOI: 10.21614/chirurgia.112.1.77Miron A., Giulea C., Nădrăgea M., Enciu O Laparoscopic Partial Adrenalectomy. Chirurgia (Bucur). 2017;112(1):77–81. DOI: 10.21614/chirurgia.112.1.77Miron A., Toma E.A., Enciu O. Partial adrenalectomy — how far can we go? Acta Endocrinol. (Buchar). 2022;18(3):401–405. DOI: 10.4183/aeb.2022.401Miron A., Toma E.A., Enciu O. Partial adrenalectomy — how far can we go? Acta Endocrinol. (Buchar). 2022;18(3):401–405. DOI: 10.4183/aeb.2022.401Billmann F., Billeter A., Thomusch O., Keck T., El Shishtawi S., Langan E.A., Strobel O., Müller-Stich B.P. Minimally invasive partial versus total adrenalectomy for unilateral primary hyperaldosteronism-a retrospective, multicenter matched-pair analysis using the new international consensus on outcome measures. Surgery. 2021;169(6):1361–1370. DOI: 10.1016/j.surg.2020.09.005Billmann F., Billeter A., Thomusch O., Keck T., El Shishtawi S., Langan E.A., Strobel O., Müller-Stich B.P. Minimally invasive partial versus total adrenalectomy for unilateral primary hyperaldosteronism-a retrospective, multicenter matched-pair analysis using the new international consensus on outcome measures. Surgery. 2021;169(6):1361–1370. DOI: 10.1016/j.surg.2020.09.005Balescu I., Arnautu O., Grasu M., Badiu C., Tomulescu V., Copăescu C. Partial adrenalectomy — arguments for the minimally invasive surgical approach. Chirurgia (Bucur). 2019;114(5):611–621. DOI: 10.21614/chirurgia.114.5.611Balescu I., Arnautu O., Grasu M., Badiu C., Tomulescu V., Copăescu C. Partial adrenalectomy — arguments for the minimally invasive surgical approach. Chirurgia (Bucur). 2019;114(5):611–621. DOI: 10.21614/chirurgia.114.5.611Procopio P.F., Pennestrì F., De Crea C., Voloudakis N., Bellantone R., Raff aelli M. Outcome of Partial Adrenalectomy in MEN2 Syndrome: Personal Experience and Systematic Review of Literature. Life (Basel). 2023;13(2):425. DOI: 10.3390/life13020425Procopio P.F., Pennestrì F., De Crea C., Voloudakis N., Bellantone R., Raff aelli M. Outcome of Partial Adrenalectomy in MEN2 Syndrome: Personal Experience and Systematic Review of Literature. Life (Basel). 2023;13(2):425. DOI: 10.3390/life13020425Flammia R.S., Anceschi U., Tufano A., Bologna E., Proietti F., Bove A.M., Misuraca L., Mastroianni R., Tirone G., Carrara A., Luciani L., Cai T., Leonardo C., Simone G. Minimally Invasive Partial vs. Total Adrenalectomy for the Treatment of Unilateral Primary Aldosteronism: A Systematic Review and Meta-Analysis. J. Clin. Med. 2022;11(5):1263. DOI: 10.3390/jcm11051263Flammia R.S., Anceschi U., Tufano A., Bologna E., Proietti F., Bove A.M., Misuraca L., Mastroianni R., Tirone G., Carrara A., Luciani L., Cai T., Leonardo C., Simone G. Minimally Invasive Partial vs. Total Adrenalectomy for the Treatment of Unilateral Primary Aldosteronism: A Systematic Review and Meta-Analysis. J. Clin. Med. 2022;11(5):1263. DOI: 10.3390/jcm11051263Van de Wiel E.C.J., Küsters B., Mann R., Veltien A., Aalders T.W., Verhaegh G.W., Mukai K., Deinum J., Langenhuijsen J.F. Partial adrenalectomy carries a considerable risk of incomplete cure in primary aldosteronism. J. Urol. 2021;206(2):219–228. DOI: 10.1097/JU.0000000000001752Van de Wiel E.C.J., Küsters B., Mann R., Veltien A., Aalders T.W., Verhaegh G.W., Mukai K., Deinum J., Langenhuijsen J.F. Partial adrenalectomy carries a considerable risk of incomplete cure in primary aldosteronism. J. Urol. 2021;206(2):219–228. DOI: 10.1097/JU.0000000000001752Takumi K., Kanako K.K., Masao O., Tomoko T., Yuya T., Haremaru K., Yuto Ya., Hironobu S., Jun S., Tetsuo N. Precise mapping of intra-adrenal aldosterone activities provides a novel surgical strategy for primary aldosteronism. J. Hypertension. 2020;76:976–984. DOI: 10.1161/hypertensionaha.119.14341Takumi K., Kanako K.K., Masao O., Tomoko T., Yuya T., Haremaru K., Yuto Ya., Hironobu S., Jun S., Tetsuo N. Precise mapping of intra-adrenal aldosterone activities provides a novel surgical strategy for primary aldosteronism. J. Hypertension. 2020;76:976–984. DOI: 10.1161/hypertensionaha.119.14341Zhou Y., Wang D., Liu Q., Hou J., Wang P. Case report: Percutaneous adrenal arterial embolization cures resistant hypertension. Front Cardiovasc. Med. 2022;9:1013426. DOI: 10.3389/fcvm.2022.1013426Zhou Y., Wang D., Liu Q., Hou J., Wang P. Case report: Percutaneous adrenal arterial embolization cures resistant hypertension. Front Cardiovasc. Med. 2022;9:1013426. DOI: 10.3389/fcvm.2022.1013426Van der Walt I.S., Brown M., Lodh S. Adrenal gland-sparing transcatheter embolisation of an aldosteronoma for the treatment of refractory hypertension. Radiol. Case Rep. 2022;17(4):1088–1094. DOI: 10.1016/j.radcr.2022.01.043Van der Walt I.S., Brown M., Lodh S. Adrenal gland-sparing transcatheter embolisation of an aldosteronoma for the treatment of refractory hypertension. Radiol. Case Rep. 2022;17(4):1088–1094. DOI: 10.1016/j.radcr.2022.01.043Dong H., Zou Y., He J., Deng Y., Chen Y., Song L., Xu B., Gao R., Jiang X. Superselective adrenal arterial embolization for idiopathic hyperaldosteronism: 12-month results from a proof-of-principle trial. Catheter Cardiovasc. Interv. 2021;97(2):976–981. DOI: 10.1002/ccd.29554Dong H., Zou Y., He J., Deng Y., Chen Y., Song L., Xu B., Gao R., Jiang X. Superselective adrenal arterial embolization for idiopathic hyperaldosteronism: 12-month results from a proof-of-principle trial. Catheter Cardiovasc. Interv. 2021;97(2):976–981. DOI: 10.1002/ccd.29554Ishikawa T., Morimoto S., Ichihara A. Eff ects of mineralocorticoid receptor antagonists on sex hormones and body composition in patients with primary aldosteronism. Hypertens. Res. 2022;45(3):496– 506. DOI: 10.1038/s41440-021-00836-6Ishikawa T., Morimoto S., Ichihara A. Eff ects of mineralocorticoid receptor antagonists on sex hormones and body composition in patients with primary aldosteronism. Hypertens. Res. 2022;45(3):496– 506. DOI: 10.1038/s41440-021-00836-6Qiu J., Li N., Xiong H.L., Yang J., Li Y.D., Hu C.K., Lai Z.Q., Liang N.P., Zhang H.J., Jiang X.J., Dong Y.F. Superselective adrenal arterial embolization for primary aldosteronism without lateralized aldosterone secretion: an effi cacy and safety, proof-of-principle study. Hypertens. Res. 2023 Mar 3. DOI: 10.1038/s41440-023-01236-8Qiu J., Li N., Xiong H.L., Yang J., Li Y.D., Hu C.K., Lai Z.Q., Liang N.P., Zhang H.J., Jiang X.J., Dong Y.F. Superselective adrenal arterial embolization for primary aldosteronism without lateralized aldosterone secretion: an effi cacy and safety, proof-of-principle study. Hypertens. Res. 2023 Mar 3. DOI: 10.1038/s41440-023-01236-8

The authors declare that there are no conflicts of interest present.